Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Hideyuki Yamato is active.

Publication


Featured researches published by Hideyuki Yamato.


Oncology | 1988

Antitumor and other effects of 24R,25-dihydroxycholecalciferol in Lewis lung carcinoma causing abnormal calcium metabolism in tumor-bearing mice.

Yuji Maeda; Hideyuki Yamato; Tohru Hirai; Takayoshi Fujii; Yasuhiko Kobayashi; Ken-ichi Saitoh; Eiji Inoguchi; Michinori Hakozaki; Hiroko Iijima; Tohru Kodaira; Yutaka Konai; Tadaaki Katoh; Chikao Yoshikumi; Yoshio Kawai; Kikuo Nomoto

Lewis lung carcinoma was found to cause hypercalcemia in tumor-bearing mice. 24R,25(OH)2D3 (K-DR, prepared by Kureha Chemical Ind.) significantly prolonged the survival time of mice with Lewis lung carcinoma. K-DR exhibited an antimetastatic effect on Lewis lung carcinoma, and also had an analgesic effect in mice with Lewis lung carcinoma.


Oncology | 1988

Cytotoxic Effects of 24/R,25-Dihydroxycholecalciferol on the Proliferation of Various Tumor Cell Lines in vitro and Its Antitumor Effects in vivo

Yuji Maeda; Tohru Hirai; Hideyuki Yamato; Kenichi Matsunaga; Yoshiharu Oguchi; Makoto Yoshimura; Takayoshi Fujii; Yasuhiko Kobayashi; Ken-ichi Saitoh; Eiji Inoguchi; Michinori Hakozaki; Hiroko Iijima; Tohru Kodaira; Yutaka Konai; Tadaaki Katoh; Chikao Yoshikumi; Yoshio Kawai; Kikuo Nomoto

24R,25(OH)2D3, one of the endogenous active metabolites of vitamin D3, showed suppressive effects on the proliferation of various tumor cells in vitro, and showed a suppressive effect on the growth of human osteosarcoma transplanted in nude mice. 24R,25(OH)2D3 increased bone strength lowered by the tumor burden which causes abnormal calcium metabolism and results in hypercalcemia.


Archive | 1984

Antiosteoporotic pharmaceutical composition containing 24,25-dihydroxycholecalciferol as an active ingredient

Yuji Maeda; Hideyuki Yamato; Takayoshi Fujii; Yasuhiko Kobayashi; Kenichi Saito; Tadaaki Kato; Chikao Yoshikumi


Archive | 1984

Pharmaceutical composition containing 24,25-dihydroxycholecalciferol as an active ingredient to treat pain, pyrexia or inflammatory diseases

Hideyuki Yamato; Yuji Maeda; Fumisato Yoshino; Kyoya Takahata; Masanori Ikuzawa; Tadaaki Kato; Chikao Yoshikumi


Archive | 1987

Method for preventing senescence and increasing bone mass

Yuji Maeda; Hideyuki Yamato; Toru Hirai; Masanori Ikuzawa; Mikio Matsuki; Masanori Togawa; Eiji Inoguchi; Sinji Nakajima; Tadaaki Kato; Chikao Yoshikumi


Archive | 1984

Pharmaceutical composition containing 24,25-dihydroxycholecalciferol as an active ingredient to treat myodystrophia

Hideyuki Yamato; Noriyuki Toyoda; Takayoshi Fujii; Yuji Maeda; Tadaaki Kato; Chikao Yoshikumi


Archive | 1984

Pharmaceutical composition containing 24,25-dihydroxycholecalciferol in methods of treatment

Hideyuki Yamato; Yuji Maeda; Fumisato Yoshino; Kyoya Takahata; Masanori Ikuzawa; Tadaaki Kato; Chikao Yoshikumi


Archive | 1988

Agent for regulating anti-oxidation mechanism in living body and containing aminobenzoic acid derivative as active component

Takami Fujii; Toru Hirai; Yukako Ishida; Shinji Nakajima; Masanori Noborikawa; Michie Shimamura; Masanori Ubusawa; Hideyuki Yamato


Archive | 1987

Method for inhibiting the formation of urinary calculus utilizing 24,25-(OH)2 -D3

Hideyuki Yamato; Yuji Maeda; Takayoshi Fujii; Yasuhiko Kobayashi; Kenichi Saito; Fumio Hirose; Tadaaki Kato; Chikao Yoshikumi


Archive | 1987

Use of 24,25-dihydroxycholecalciferol in the prophylaxis of bone senescence

Yuji Maeda; Hideyuki Yamato; Toru Hirai; Masanori Ikuzawa; Mikio Matsuki; Masanori Togawa; Eiji Inoguchi; Sinji Nakajima; Tadaaki Kato; Chikao Yoshikumi

Collaboration


Dive into the Hideyuki Yamato's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Hiroko Iijima

Hyogo College of Medicine

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge